![](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1644345670/FDA.jpg?VersionId=Y_ExpycBz5asjINKhoKywmcCRyDN8pLV)
UPDATED: Elevar, Hengrui eye accelerated refile for PD-1 liver cancer combo after surprise FDA rejection
Editor's Note: Since the story's original publication on July 10, Elevar has adjusted its expected refile timeline. And the story has been updated to reflect that. After a meeting with the FDA last week, Elevar Therapeutics and Jiangsu Hengrui …